Our practice in managing advanced NSCLC has been evolving rapidly as new studies emerge highlighting the importance of molecular markers in guiding treatment decisions and leave open questions about how to optimize the sequence of treatments from first line to second line, who to observe and who to recommend for maintenance therapy. And if maintenance therapy, what treatment to recommend?
If the ongoing debate have been leaving you without clear answers, join me with two other national experts to discuss how each of us approaches real life clinical situations in terms of what molecular markers we would obtain in different situations, what first line therapy we’d recommend, and how we would transition from first line to later treatments. On Wednesday, July 28th, 8 PM EDT/5 PM PST, I’ll be joined by Dr. Tom Hensing from Northshore Health Systems in Evanston and affiliated with the University of Chicago, as well as Dr. David Jackman from Dana Farber Cancer Institute in Boston as we hash out ideas together.
We may not arrive at a complete consensus, but we’ll cover the range of approaches and the current state of what is known and what remains to be decided. The event is free but limited, and you need to register in advance. We’ll plan to edit the program into a series of podcasts afterward.
The program is sponsored through an educational grant from OSI Pharmaceuticals, who have no role in developing its content. We thank them for their support of this activity.
Related posts:
Posted on July 15, 2010 at 5:32 am
Dr. West,
Great topic, and very timely after the TORCH data from ASCO. Excellent faculty, too!
Jim